Lorenz K, Sekulla C, Dralle H
Martin-Luther Universität Halle-Wittenberg, Klinik für Allgemein-, Viszeral- und Gefäßchirurgie, Halle / Saale, Deutschland.
Zentralbl Chir. 2013 Dec;138 Suppl 2:e47-54. doi: 10.1055/s-0030-1262542. Epub 2011 Feb 22.
Conservative management of renal hyperparathyroidism has changed recently. Innovative substances, especially the advent of calcimimetics, have influenced the therapeutic concept. Consequently, a decline in surgical frequency for renal hyperparathyroidism has been reported. In this context it is now mandatory to evaluate the role of surgery, the surgical strategy and procedures for renal hyperparathyroidism anew. Based on a review of the literature the current position of surgical indications and care for renal hyperparathyroidism as well as possible influences of innovative medical treatment are highlighted. In summary, the timing and indications for surgery have been influenced, however, surgery still remains the only permanently effective treatment option for renal hyperparathyroidism.
肾性甲状旁腺功能亢进的保守治疗近来已有所改变。新型药物，尤其是拟钙剂的出现，影响了治疗理念。因此，有报道称肾性甲状旁腺功能亢进的手术频率有所下降。在此背景下，现在必须重新评估手术在肾性甲状旁腺功能亢进治疗中的作用、手术策略及手术方式。基于文献综述，突出了肾性甲状旁腺功能亢进手术指征及治疗的现状以及新型药物治疗可能产生的影响。总之，手术时机和指征受到了影响，然而，手术仍然是肾性甲状旁腺功能亢进唯一永久有效的治疗选择。
